作为预防心血管疾病中血栓栓塞的新目标的XI因子:随机对照试验的元分析
Ahmed E Ali1,2, Mohamed K Awad3, Karim Ali4,2
1Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Journal of thrombosis and thrombolysis
|May 18, 2024
概括
与传统抗凝剂相比,新型XI因子 (FXI) 抑制剂在减少出血和血栓塞栓症方面表现有前途. 这些FXI药物可能为心血管疾病患者提供更安全,更有效的选择.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 血栓形成研究研究
背景情况:
- 抗凝剂治疗对于心血管疾病 (CVD) 管理至关重要.
- 传统的抗凝剂存在风险,主要是出血.
- XI因子 (FXI) 抑制剂是一个正在研究的新疗法类别.
研究的目的:
- 与安慰剂或标准抗凝药相比,评估FXI抑制剂的疗效和安全性.
- 评估FXI抑制剂对出血事件和血栓栓塞风险的影响.
- 分析FXI抑制剂对不良事件和死亡率的影响.
主要方法:
- 一个全面的文献搜索确定了11个随机对照试验.
- 10,536名患者被纳入了元分析.
- 主要结局:出血发生率和血栓栓塞. 二次结果:不良事件和死亡率.
主要成果:
- 与对照组相比,FXI抑制剂显示出减少出血和血栓栓塞的趋势.
- 与埃诺沙巴林相比,观察到显著减少出血 (RR=0.42) 和血栓塞栓症 (RR=0.59).
- 与DOAC相比,FXI抑制剂显著降低了出血,但没有降低血栓塞栓症.
结论:
- FXI 抑制剂显示出潜在的安全替代传统抗凝剂.
- 它们可以提高预防血栓栓塞的有效性,降低出血风险.
- 需要进一步的研究,以充分阐明FXI抑制剂在抗凝固中的作用.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
681
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
681
01:16Clot Retraction and Fibrinolysis
5.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.5K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
521
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521
01:09Coagulation
6.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.2K
01:24Disorders of Hemostasis
845
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
845